drugset / Trial / NCT07140328

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT07140328 ↗

Phase 2 Recruiting 50 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.

Timeline

Start
2025-04-24
Primary completion
2025-07-10
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK39004 Unknown 0.75 mg Inhaled
Subject HSK39004 Unknown 1.5 mg Inhaled
Subject HSK39004 Unknown 3 mg Inhaled